Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Podcast
What were the biggest clinical trial flops of 2025?
On this episode of "The Top Line," Fierce Biotech's James Waldron and Fierce Pharma's Fraiser Kansteiner discuss the clinical trial failures that stood out in 2025.
Ayla Ellison
,
James Waldron
,
Fraiser Kansteiner
Feb 13, 2026 11:47am
Lundbeck’s preventative migraine IV sees success in ph. 2
Feb 12, 2026 1:25pm
BridgeBio preps approval push for dwarfism drug after ph. 3 win
Feb 12, 2026 7:30am
Upstream posts Tezspire-like asthma efficacy in phase 2
Feb 11, 2026 7:24am
Nektar eczema asset 'checked all of the boxes' in phase 2
Feb 10, 2026 10:55am
Evommune's Dupixent-like eczema data drive 75% stock rally
Feb 10, 2026 9:31am